MAPT and supranuclear palsy, progressive, 1: Fig. S32a-a’’, c–c’’), while Tau-5 labelled PSP lesions, where it yielded a strong immunoreactive signal, but failed to label Tau in AD and PiD lesions altogether (Supp.